← Eichor
Study identifier: NCT03108196 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder

Condition: Bladder Cancer · Urinary Diversion  ·  Sponsor: Zhujiang Hospital

PhaseNA
Planned participants96
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient' survival and quality of life. In 1988, Hautmann firstly reported an orthotopic urinary diversion method: Hautmann neobladder. As the urine can be controlled from the original urethra, the patient's quality of life has been greatly improved, so the new bladder surgery gradually accepted and welcomed by urologists and patients. However, in order to achieve low-pressure and large-volume storage capacity of the urine reservoir, the 40-70cm long interception of terminal ileum need to be detubularized. Only after split, folded, re-stitched and a series of treatment, the intestinal can be used. Such complicated procedures make so many urologists give it up. In addition, the interception of the long ileum may lead to reduced absorption of vitamin B12 which caused anemia, metabolic acidosis, intestinal dysfunction. Not only that, as time goes by, this kind of neobladder will be unlimited expansion and resulting in a serious increase in residual urine volume, hydronephrosis, or even the occurrence of neobladder spontaneous rupture. In 2000, professor Chunxiao Liu invented "detaenial sigmoid neobladder", this surgical method overset the traditional intestinal detubularization approach, which detached the serosal layer with smooth muscle from the bowel wit…

This description comes directly from the study's public registry record.

Talk to the study team

Abai Xu, doctor  ·  +86 18665626790  ·  lc96xab@163.com

Peng Xu, doctor  ·  +86 18665073650  ·  yihuixp88@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Zhujiang HospitalGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03108196